Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness Source: Eur Respir J 2006; 27: 1144-1151 Year: 2006
Inhaled corticosteroids and growth of airway function in asthmatic children Source: Eur Respir J 2004; 23: 861-868 Year: 2004
Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma Source: Eur Respir J 2001; 17: 374-379 Year: 2001
Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma Source: Eur Respir J 2002; 20: 853-858 Year: 2002
Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD Source: Eur Respir J 2003 Dec 01;22(6):926-930 Year: 2003
Budesonide prevents but does not reverse sustained airway hyperresponsiveness in mice Source: Eur Respir J 2008; 32: 970-978 Year: 2008
Changes in objective markers following inhaled corticosteroids (ICS) in asthmatics with airway hyperresponsiveness (AHR) to mannitol Source: International Congress 2019 – Airway physiology Year: 2019
Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma Source: Eur Respir J 2006; 27: 172-187 Year: 2006
Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma Source: Eur Respir J 2009; 33: 1277-1286 Year: 2009
Dose-related effect of inhaled fluticasone on allergen-induced airway changes in rats Source: Eur Respir J 2002; 20: 873-879 Year: 2002
Single-dose desloratadine and montelukast and allergen-induced late airway responses Source: Eur Respir J 2009; 33: 1302-1308 Year: 2009
Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison Source: Eur Respir J 2007; 30: 653-661 Year: 2007
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Severe therapy resistant asthma Source: ISSN=1025-448x, ISBN=1-904097-26-x, page=312 Year: 2003
Rapid protective effect of inhaled fluticasone on airway hyperresponsiveness to AMP in patients with fixed airway obstruction due to asthma but not COPD Source: Eur Respir J 2006; 28: Suppl. 50, 670s Year: 2006
Assessment of bronchial hyperreactivity, maximal airway response and response to inhaled corticosteriod treatment in patients with bronchiectasis Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring Year: 2007
Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function Source: Eur Respir J 2008; 32: 989-996 Year: 2008
Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2 -agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003
Fluticasone furoate, a novel inhaled corticosteroid (ICS), provides sustained protection against amp airway hyperresponsiveness (AHR) in mild asthma Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Dissociation in effects of fluticasone but not fluticasone/salmeterol on lung function and airway hyperresponsiveness in mild persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 385s Year: 2002